Idera Pharmaceuticals, Inc. (IDRA) Reports Second Quarter 2014 Financial Results And Provides Corporate Update
8/12/2014 8:44:39 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial and operational results for the quarter ended June 30, 2014. The Company highlighted progress in advancing drug candidates for the treatment of mutation-specific forms of B-cell lymphoma and autoimmune diseases, as well as its next-generation antisense technology platform.
Help employers find you! Check out all the jobs and post your resume.
comments powered by